SCHEMBL5724210

SCHEMBL5724210

CC(C)(C)C1CN(c2nc(C(=O)N3CCCC3)cs2)C1O[SiH](c1ccccc1)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
HPGD P15428 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
ALDH1A1 P00352 1/20 0.38
ALOX15 P16050 1/20 0.38
HSD17B10 Q99714 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KDM4E B2RXH2 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
ATM Q13315 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
HTR2C P28335 6/20 0.37
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
TRPC3 Q13507 2/20 0.35
TRPC6 Q9Y210 2/20 0.35
USP30 Q70CQ3 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5724200 0.99 MEN1 (0.39) NPC1RAB9AHPGDSMN1; SMN2ALDH1A1
SCHEMBL5724282 0.98 HTR2C (0.37) NPC1RAB9AHPGDSMN1; SMN2ALDH1A1
SCHEMBL5724456 0.94 HTR2C (0.45) NPC1RAB9ASMN1; SMN2ALDH1A1HSD17B10
SCHEMBL5724120 0.93 TSHR (0.38) NPC1RAB9AHPGDSMN1; SMN2ALDH1A1
SCHEMBL5724416 0.93 HTR2C (0.36) NPC1RAB9AHPGDSMN1; SMN2ALDH1A1
SCHEMBL5724523 0.89 RIPK1 (0.35) MEN1KMT2AHTR2CHCRTR1HCRTR2
SCHEMBL5724737 0.88 LDHA (0.41) ALDH1A1L3MBTL1KDM4E
SCHEMBL5724075 0.86 SCD (0.40) HCRTR1HCRTR2USP30
SCHEMBL5724321 0.83 TDP1 (0.42) NPC1RAB9AHPGDSMN1; SMN2ALDH1A1
SCHEMBL5723868 0.83 NPC1 (0.41) NPC1RAB9AHPGDSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1340757-B1 1-METHYLCARBAPENEM DERIVATIVES SANKYO CO (JP) 2006-10-11 EP disclosed
US-7001897-B2 1-methylcarbapenem derivatives SANKYO COMPANY, LIMITED (JP) 2006-02-21 US disclosed
US-20040014962-A1 1-Methylcarbapenem derivatives SANKYO COMPANY, LIMITED (JP) 2004-01-22 US disclosed
EP-1340757-A1 1-METHYLCARBAPENEM DERIVATIVES Sankyo Company, Limited (JP) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014962-A1 1-Methylcarbapenem derivatives CD14, CPT1A, ACMSD NPC1 383/4885RAB9A 3028/4885HPGD 1268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.